iData Insights

Thrombocytopenia - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 02, 2016 16:33 IST

This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope

The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Thrombocytopenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=167709/thrombocytopenia-pipeline-insights-2016

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=167709/thrombocytopenia-pipeline-insights-2016

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Thrombocytopenia Overview 11

Therapeutics Development 12

Pipeline Products for Thrombocytopenia - Overview 12

Pipeline Products for Thrombocytopenia - Comparative Analysis 13

Thrombocytopenia - Therapeutics under Development by Companies 14

Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes 16

Thrombocytopenia - Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Thrombocytopenia - Products under Development by Companies 20

Thrombocytopenia - Products under Investigation by Universities/Institutes 23

Thrombocytopenia - Companies Involved in Therapeutics Development 24

3SBio Inc. 24

Amarillo Biosciences, Inc. 25

Amgen Inc. 26

Arcturus Therapeutics, Inc 27

aTyr Pharma, Inc. 28

Baxalta Incorporated 29

Bayer AG 30

BioLineRx, Ltd. 31

Boehringer Ingelheim GmbH 32

Bolder Biotechnology, Inc. 33

Bristol-Myers Squibb Company 34

Cellerant Therapeutics, Inc. 35

Eisai Co., Ltd. 36

Hansa Medical AB 37

Immunomedics, Inc. 38

Intas Pharmaceuticals Ltd. 39

Jiangsu Hengrui Medicine Co., Ltd. 40

Merck & Co., Inc. 41

Momenta Pharmaceuticals, Inc. 42

Myelo Therapeutics GmbH 43

Neumedicines Inc. 44

Novartis AG 45

Pfizer Inc. 46

PhytoHealth Corporation 47

Prophylix Pharma AS 48

Protalex, Inc. 49

Rigel Pharmaceuticals, Inc. 50

Shionogi & Co., Ltd. 51

STATegics, Inc. 52

ViroMed Co., Ltd. 53

Thrombocytopenia - Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Target 55

Assessment by Mechanism of Action 57

Assessment by Route of Administration 59

Assessment by Molecule Type 61

Drug Profiles 63

Antibody for Autoimmune Disorders and Inflammation - Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

avatrombopag - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

BBT-059 - Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

BI-655064 - Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

BL-8040 - Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

BMS-986004 - Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

CLT-009 - Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

eltrombopag olamine - Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

eltrombopag olamine - Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

fostamatinib disodium - Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

GL-2045 - Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

GSK-2285921 - Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Hetrombopag Olamine - Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

interferon alfa - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

LUNAR-TPO - Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

lusutrombopag - Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

MK-8723 - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Monoclonal Antibody to Agonize TpoR for Thrombocytopenia - Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Myelo-001 - Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

NMIL-121 - Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

Oligonucleotides to Activate miRNA-150 for Thrombocytopenia - Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

PBF-1509 - Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

PEG-VM501 - Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

PHN-013 - Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

PRTX-100 - Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

rivaroxaban - Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

romiplostim - Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

romiplostim biosimilar - Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

SM-101 - Drug Profile 111

Product Description 111

Mechanism of Action 111

R&D Progress 111

Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

Small Molecules to Inhibit PF4 for HIT - Drug Profile 115

Product Description 115

Mechanism of Action 115

R&D Progress 115

STST-4 - Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

Tmax - Drug Profile 117

Product Description 117

Mechanism of Action 117

R&D Progress 117

Tromplate - Drug Profile 118

Product Description 118

Mechanism of Action 118

R&D Progress 118

TXA-302 - Drug Profile 119

Product Description 119

Mechanism of Action 119

R&D Progress 119

veltuzumab - Drug Profile 121

Product Description 121

Mechanism of Action 121

Read More http://www.idatainsights.com/reports-landing-page.php?id=167709/thrombocytopenia-pipeline-insights-2016

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.